Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00387
|
|||||
| Drug Name |
Omeprazole
|
|||||
| Synonyms |
(-)-Omeprazole; 2-(((3,5-Dimethyl-4-methoxy-2-pyridyl)methyl)sulfinyl)-5-methoxy-1H-benzimidazole; 2-({[3,5-dimethyl-4-(methyloxy)pyridin-2-yl]methyl}sulfinyl)-5-(methyloxy)-1H-benzimidazole; 5-Methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole; 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole; 5-Methoxy-2[(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl]-1H-benzimidazole; 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole; 6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole; AGI-010; AULCER; Antra; Antra MUPS; Audazol; Axagon; Belmazol; Ceprandal; DM-3458; Danlox; Demeprazol; Desec; Dizprazol; Dudencer; Elgam; Emeproton; Emilok; Epirazole; Erbolin; Esomeprazol; Esomeprazole; Esomperazole; Esopral; Exter; Gasec; Gastrimut; Gastroloc; Gibancer; H 168-68; H 168/68; H-168/68; Indurgan; Inhibitron; Inhipump; Lensor; Logastric; Lomac; Losec; Losec (TN); Losec, Omesec, Prilosec, Zegerid, Omeprazole; Lucen; Mepral; Miol; Miracid; Mopral; Morecon; Nexium; Nexium IV; Nilsec; Nopramin; Nuclosina; O0359; OMEP; OMZ; Ocid; Olexin; Olit; Omapren; Omebeta; Omebeta 20; Omed; Omegast; Omepradex; Omepral; Omeprazol; Omeprazol [INN-Spanish]; Omeprazole (JAN/USP/INN); Omeprazole [USAN:INN:BAN:JAN]; Omeprazole delayed-release; Omeprazole magnesium; Omeprazolum; Omeprazolum [INN-Latin]; Omeprazon; Omeprazone; Omeprol; Omesek; Omez; Omezol; Omezolan; Omid; Omisec; Omizac; Ompanyt; Ortanol; Osiren; Ozoken; Paprazol; Parizac; Pepticum; Pepticus; Peptilcer; Prazentol; Prazidec; Prazolit; Prilosec; Prilosec (TN); Prilosec OTC; Procelac; Proclor; Prysma; Ramezol; Regulacid; Result; SAN-15; Sanamidol; Secrepina; Tedec Ulceral; Ulceral; Ulcesep; Ulcometion; Ulcozol; Ulcsep; Ulsen; Ultop; Ulzol; Victrix; Zefxon; Zegerid; Zepral; Zimor; Zoltum
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Gastroesophageal reflux disease [ICD11:DA22] | Approved | [1] | |||
| Therapeutic Class |
Antiulcer Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C17H19N3O3S
|
|||||
| Canonical SMILES |
CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC
|
|||||
| InChI |
InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)
|
|||||
| InChIKey |
SUBDBMMJDZJVOS-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 73590-58-6
|
|||||
| Pharmaceutical Properties | Molecular Weight | 345.4 | Topological Polar Surface Area | 96.3 | ||
| Heavy Atom Count | 24 | Rotatable Bond Count | 5 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 6 | |||
| XLogP |
2.2
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10321754
,11112840
,11398365
,11466521
,11467641
,11486042
,11528599
,12013167
,14753960
,14875946
,22391484
,24897870
,26751452
,26751453
,26759296
,29223683
,3281991
,46386973
,46487906
,46509065
,4696242
,47365309
,47589088
,47589089
,48035237
,48170542
,48414255
,48416351
,49681572
,49698521
,49834935
,50100529
,50103932
,5212304
,53788700
,56313300
,56313696
,56313928
,56422106
,57322340
,640212
,7847521
,7980199
,80295314
,81093370
,8152819
,85174452
,855576
,85788870
,9532
|
|||||
| ChEBI ID |
ChEBI:7772
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Omeprazole was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.